Understanding the variability in ketamine’s efficacy in managing treatment-resistant depression

Ketamine, known for its illicit recreational use, is an approved treatment for treatment-resistant depression. It works by blocking NMDA receptors, which increases glutamate in mood-regulating brain regions and promotes synaptic plasticity and neurogenesis, counteracting chronic stress effects. Response varies among individuals, influenced by route of administration, dose, delivery rate, past trauma, and genetic predispositions. There is growing interest in combining ketamine with therapies like Cognitive Behavioural Therapy and Mindfulness-Based Interventions to enhance outcomes.

Study at a glance

Abstract

Abstract Ketamine, often associated with its frequent illicit recreational use, is renowned as an approved alternative for treatment-resistant depression. This paper evaluates the mechanism of ketamine’s role in treating depression, emphasising its positive safety profile and acute onset of action. Ketamine’s mechanism of action involves antagonism of N-methyl-D-Aspartate (NMDA) receptors, leading to increased glutamate production in brain regions associated with mood regulation. Moreover, ketamine counteracts the effects of chronic stress by promoting synaptic plasticity and neurogenesis. However, the response to ketamine varies among individuals, prompting the need for further investigation into the factors influencing its efficacy, such as route of administration, dose and the rate at which it is delivered. Other variables such as past traumatic experiences and genetic predispositions may also play a significant role in determining an individual’s response to ketamine therapy, raising the importance of tailored treatment approaches. Furthermore, there is growing interest in investigating the synergy of ketamine alongside other therapeutic modalities, including Cognitive Behavioural Therapy (CBT) and Mindfulness-Based Interventions (MBIs), as a means to enhance treatment outcomes in modern psychiatry.